#### DRAFT STATUTORY INSTRUMENTS

## 2019 No.

# The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019

### PART 5

Amendment of Part 5 (marketing authorisations)

# Amendment of Schedule 8 (material to accompany an application for a UK marketing authorisation)

- **50.**—(1) Schedule 8(1) is amended as follows.
- (2) In paragraph 12—
  - (a) in sub-paragraph (a), after "pharmacovigilance" insert "who is ordinarily resident, and operates, in the United Kingdom";
  - (b) omit sub-paragraph (b); and
  - (c) in paragraph (e) at the end insert "or, if kept in electronic form, from which it can be accessed, which in either case, must be in the United Kingdom".
- (3) For paragraph 18 substitute—
  - "18. Where an application for authorisation for the medicinal product to be placed on the market is under consideration in a country other than the United Kingdom, or by the EMA, notification of that fact."
- (4) In paragraph 19, for "a member state or by a third country", substitute "a country other than the United Kingdom or by the European Commission".
  - (5) Omit paragraph 20.
- (6) In paragraph 21, for "a member state or by a third country", substitute "a country other than the United Kingdom".
  - (7) Omit paragraph 22.
  - (8) In paragraph 23—
    - (a) for "Article 23 of Regulation (EC) No 726/2004" substitute "regulation 202A";
    - (b) before "statement", insert "symbol and"; and
    - (c) before "This", insert "▼".
  - (9) After paragraph 25, insert—
    - "25A. In the case of an advanced therapy medicinal product which contains cells or tissues, a detailed description of those cells or tissues and of their specific origin, including the species of animal in cases of non-human origin."
  - (10) After paragraph 35, insert—

- "36. In the case of an advanced therapy medicinal product—
  - (a) references in this Part of this Schedule to administration of a product include references to the advanced therapy medicinal product's use, application or implantation; and
  - (b) descriptions, instructions and warnings must include explanatory drawings and pictures where necessary.".